Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.

Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Franco DR, Kahn SE, Lincoff AM, Martins RF, McGuire DK, Mehta V, Miller D, Nauck MA, Nishiyama H, Nissen SE, Nyolczas N, Sattar N, Weerakkody G, Wiese RJ, Zinman B, Zoungas S, D'Alessio D, SURPASS-CVOT investigators

Open source

DOI: 10.1093/eurjpc/zwag452
Published: 2026 Oct 15
Container: European journal of preventive cardiology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/eurjpc/zwag452,
  title = {Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.},
  author = {Nicholls SJ and Pavo I and Bhatt DL and Buse JB and Del Prato S and Franco DR and Kahn SE and Lincoff AM and Martins RF and McGuire DK and Mehta V and Miller D and Nauck MA and Nishiyama H and Nissen SE and Nyolczas N and Sattar N and Weerakkody G and Wiese RJ and Zinman B and Zoungas S and D'Alessio D and SURPASS-CVOT investigators},
  year = {2026},
  journal = {European journal of preventive cardiology},
  doi = {10.1093/eurjpc/zwag452},
  url = {https://doi.org/10.1093/eurjpc/zwag452}
}

RIS

TY  - JOUR
TI  - Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.
AU  - Nicholls SJ
AU  - Pavo I
AU  - Bhatt DL
AU  - Buse JB
AU  - Del Prato S
AU  - Franco DR
AU  - Kahn SE
AU  - Lincoff AM
AU  - Martins RF
AU  - McGuire DK
AU  - Mehta V
AU  - Miller D
AU  - Nauck MA
AU  - Nishiyama H
AU  - Nissen SE
AU  - Nyolczas N
AU  - Sattar N
AU  - Weerakkody G
AU  - Wiese RJ
AU  - Zinman B
AU  - Zoungas S
AU  - D'Alessio D
AU  - SURPASS-CVOT investigators
PY  - 2026
JO  - European journal of preventive cardiology
DO  - 10.1093/eurjpc/zwag452
UR  - https://doi.org/10.1093/eurjpc/zwag452
ER  -

APA

SJ, N., I, P., DL, B., JB, B., S, D. P., DR, F., SE, K., AM, L., RF, M., DK, M., V, M., D, M., MA, N., H, N., SE, N., N, N., N, S., G, W., RJ, W., B, Z., S, Z., D, D., & investigators, S. (2026). Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.. European journal of preventive cardiology. https://doi.org/10.1093/eurjpc/zwag452

Source records

pubmed · retrieved 2026-11-10T11:52:07.067Z